NCT04769518: ARRCII

Advanced Recovery Room Care II - Improved Recovery After Surgery

Terminated NA Last updated 5 April 2022

What this trial tests

NA trial testing Advanced Recovery Room Care (ARRC) in Postoperative Complications in 857 participants. Terminated before completion.

Timeline

1 March 2021

Primary endpoint
24 March 2022

24 March 2022

Quick facts

Lead sponsor	University of Adelaide
Phase	NA
Status	Terminated
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	857
Start date	1 March 2021
Primary completion	24 March 2022
Estimated completion	24 March 2022
Sites	1 location across Australia

Drugs / interventions tested

• Advanced Recovery Room Care (ARRC)

Conditions studied

• Postoperative Complications — all drugs for Postoperative Complications →
• Cost-Benefit Analysis — all drugs for Cost-Benefit Analysis →

Sponsor

University of Adelaide

Who can join

18 and older, any sex, with Postoperative Complications or Cost-Benefit Analysis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Moderate-risk surgical patients have a very high incidence of early serious postoperative complications (approximately 50% at Royal Adelaide Hospital, RAH). This affects patients' wellbeing and produces a high rate of unplanned postoperative hospital re-admissions. This is also costly, and patients unnecessarily fill approximately 4000 RAH bed days annually.

A trial of a new model of enhanced care after surgery (Advanced Recovery Room Care, 'ARRC') demonstrated that complications were quickly identified and expertly addressed. Re-admission days appeared to decrease by 80%. Business and economic analysis showed (i) patients can expect 3 extra days at home, (ii) 4000 bed days can be freed annually, and (iii) better care at lesser cost (technically, ICER = -$600/day at home). Freeing hospital beds, and rapid cost savings, are critical in this Covid era.

This trial re-introduces ARRC for Orthopaedic, Colorectal, Gynae-Oncology and Neurosurgery, and other specialties, and formally examines patient outcomes and costs compared to eligible patient who do not receive ARRC. Data from patient progress and vital signs are to be used to improve patient risk stratification and triage at defined timepoints before, during, and after surgery. This may allow better and earlier identification of patients (not) needing ongoing ARRC, potentially reducing costs of care further without affecting safety. A Markov cost-effectiveness model provides the platform for cost effectiveness outcomes (Days at Home V Cost).

Publications & conference data

No peer-reviewed publications indexed yet for this trial.